Amid a record bad year, Bel­licum keeps tak­ing its lumps as FDA slams tri­al hold on CAR-T hope­ful

It’s been no less than a dis­as­trous year for Hous­ton biotech Bel­licum Phar­ma­ceu­ti­cals af­ter tak­ing a scalpel to its pipeline and dump­ing a vast ma­jor­i­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.